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Abstract 
Background: Type-2 diabetes mellitus is one of the major risk factors of atherosclerosis, particularly in peripheral 
artery disease (PAD). Several studies have documented a correlation between omentin-1 serum levels, atherosclerosis, 
and cardiovascular diseases. However, a clear link between circulating omentin-1 and PAD in diabetic patients has yet 
to be established. The aim of this study was to investigate the potential role of omentin-1 in PAD in type-2 diabetic 
patients.
Methods: In this cross-sectional study, we analyzed omentin-1 serum levels by ELISA in 600 type-2 diabetic patients 
with (n = 300) and without (n = 300) PAD at Fontaine’s stage II, III, or IV.
Results: We found that omentin-1 serum levels were significantly lower in diabetic patients with PAD than in diabetic 
controls (29.46 vs 49.24 ng/mL, P < 0.001) and that the levels gradually decreased in proportion to disease severity 
(P < 0.05). The association between omentin-1 levels and PAD remained significant after adjusting for major risk factors 
in a multivariate analysis.
Conclusions: Our results suggest that omentin-1 is reduced in type 2 diabetic patients with PAD and that omentin-1 
levels are related to disease severity.
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Background
Peripheral artery disease (PAD) represents a frequent 
manifestation of atherosclerosis disease. Approximately 
202 million people worldwide are suffering from lower 
extremity artery disease [1]. The prevalence of PAD 
increases with the prevalence of type-2 diabetes melli-
tus (T2DM), one of the major risk factors of atheroscle-
rosis. Furthermore, PAD has special features and poorer 
prognosis in diabetic patients than in non-diabetic 
patients. Patients with T2DM are a high-risk group for 
developing extensive vascular disease, which adversely 
affects quality of life. PAD, in these patients, represents 
an important public health problem, with a significant 
impact on healthcare and a heavy economic burden 
[2]. Consequently, early diagnosis and management of 
PAD in T2DM patients are critical for reducing the risk 
of major adverse cardiovascular events (MACE) and 
major adverse limb events (MALE), minimizing the risk 
of long-term disability [3]. International guidelines [4] 
addressing diagnosis, treatment, and overall management 
of patients with PAD suggest the ankle–brachial index 
(ABI) as an initial diagnostic test for PAD. However, ABI 
evaluation has a low sensitivity for detecting the initial 
stages of PAD, and it may not be applicable in patients 
with diabetes because of calcification of the artery walls, 
which can increase vessel stiffness [5].
Therefore, to be able to make an early diagnosis, we 
need to identify novel biomarkers that can detect PAD 
among diabetic patients.
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In the past few years, attention has been focused on 
adipokines, cytokines produced and secreted by visceral 
adipose tissue and involved in the development of ath-
erosclerotic disease. Studies have shown that some of 
these cytokines take part in the regulation of adipose tis-
sue with a pro- or anti-inflammatory effect, and several 
researchers are investigating their possible role as bio-
markers for metabolic disorders [6]. In this context, find-
ings have documented a possible role of omentin serum 
levels in cardiovascular diseases. Omentin, a type of adi-
pokine, is a hydrophilic protein with a molecular weight 
of 40  kDa; it is composed of 313 amino acids and is 
encoded by a gene present in chromosomal region 1q22–
q23, which is related to T2DM [7]. This protein’s mRNA 
is expressed mainly in the fraction of the vascular stroma 
of the visceral adipose tissue, and poorly in subcutaneous 
adipose tissue and mature adipocytes. Omentin mRNA 
has also been identified in other tissues, such as endothe-
lial cells, epicardial adipose tissue [8], thymus, small 
intestine, colon, reticulocytes, ovary, lung, and placenta. 
There are two main homologous isoforms: omentin-1, 
the most common form in human plasma; and omen-
tin-2, which shares 83% of amino acids with isoform 1 [9]. 
Currently, the omentin-binding receptors are unknown 
[10]. Basic and clinical research has documented an anti-
inflammatory action of omentin-1 and a mainly negative 
correlation between its plasma levels and insulin resist-
ance, diabetes, obesity, and metabolic syndrome. Yoo 
and coworkers and Liu and colleagues, in cross-sectional 
studies, have documented that omentin-1 levels are 
reduced in patients with T2DM and metabolic syndrome, 
especially in patients with carotid plaques, compared to 
healthy subjects, diabetic subjects, or patients with meta-
bolic syndrome without carotid atheromasia [11, 12]. 
More recent data have shown that, in general, the reduc-
tion of plasma levels of omentin increases the risk of dia-
betes and of atherosclerotic complications [13]. These 
observations have suggested a possible role of omentin-1 
in atherosclerotic disease.
Other studies have investigated the relationship 
between omentin-1 and coronary artery disease [14, 15], 
stroke, and complications of T2DM [13, 16]. Based on 
these findings, some controversial data emerged about 
a negative, positive, or independent correlation between 
omentin-1 levels and cardiovascular risk factors. The 
analysis of these results revealed a different behavior of 
omentin-1 in healthy subjects compared to subjects with 
pre-existing metabolic disease [17, 18].
Only few, non-conclusive data exist regarding omen-
tin-1 and PAD in non-diabetic patients [19] and a defini-
tive link between circulating omentin-1 and PAD in 
diabetic patients has not yet been established.
The aim of this study was to investigate the potential 
role of omentin-1 in PAD of type-2 diabetic patients.
Methods
Study population
We performed a cross-sectional study of diabetic patients 
consecutively admitted to the Department of Vascu-
lar Diseases of the Fondazione Policlinico Universitario 
A. Gemelli IRCCS, Roma, Italy, from 1 October 2015 to 
31 June 2018. To be enrolled in the present study, each 
patient had to fulfill the inclusion criteria shown in 
Table  1. We enrolled diabetic patients with or without 
PAD. Type-2 diabetes mellitus was defined as a fasting 
plasma glucose level ≥ 126  mg/dl and/or a HbA1c level 
≥ 6.5% or as a medical history of diabetes plus treatment 
with diabetes medication. Each patient enrolled in the 
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age older than 40 affected by type 2 diabetes mel-
litus
Inability or refusal to sign informed consent for inclusion of the study
Renal failure with eGFR < 30 ml/min
State of pregnancy established or presumed
History of solid or hematological neoplasia or active neoplasia
Transplant holder of a solid organ or subjected to bone marrow transplantation
Gastro-intestinal resection
Unfavorable prognosis at the judgment of the clinician, or life expectancy of less than 12 months
Autoimmune or chronic inflammatory pathology
Confirmed liver cirrhosis with Child–Pugh C functional impairment
Confirmed or suspected monogenic hereditary dyslipidemia
Confirmed acquired platelets or congenital platelets disease
Confirmed congenital hemorrhagic diathesis or acquired coagulopathies; Congenital or acquired 
thrombophilia
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study was assessed by a history of PAD symptoms or a 
confirmed PAD diagnosis, according to previous crite-
ria established by the Ad Hoc Committee on Reporting 
Standards of the Society for Vascular Surgery and the 
International Society for Cardiovascular Surgery [20, 
21]. Patients with clinical findings consistent with PAD 
underwent ABI measurement, and both lower limbs 
were assessed using arterial Doppler-enhanced ultra-
sonography, computed tomography angiography, lower 
limb angiography, at the attending physician’s judgment. 
Patients with an ABI > 0.90 and without symptoms of 
PAD did not undergo further testing and were deemed to 
be without PAD.
The extent of PAD was determined by using the Fon-
taine classification, which defines four stages: stage I, 
asymptomatic; stage II, intermittent claudication; stage 
III, rest pain; stage IV, ischemic ulcers or gangrene [22].
Patients enrolled were also assessed by a history of 
heart failure symptoms or a confirmed diagnosis, as pre-
viously described [23].
The study was approved by the Ethics Committee of the 
Fondazione Policlinico Universitario A. Gemelli IRCCS 
and adhered to the principles of the Declaration of Hel-
sinki. All patients enrolled gave their informed consent.
Biochemical measurements
All patients enrolled underwent a blood test after an 
overnight fasting period of 8  h. For every patient, fast-
ing glucose, triglycerides, total cholesterol, and low- and 
high-density lipoprotein were determined. Renal func-
tion was assessed using estimated glomerular filtration 
rate (eGFR), which was calculated using the modification 
of diet in renal disease (MDRD) formula. Serum obtained 
and separated by centrifugation of blood samples was 
stored at − 80  °C before every measurement. Serum 
omentin-1 levels were determined by a commercially 
available ELISA kit (E-EL-H2028, Elabscience) accord-
ing to its protocol. The intra- and inter-assay coefficients 
of variation were 3.5% and 10.5%, respectively. The sen-
sitivity, defined as the mean ± 3 SD of the 0 standard, 
was calculated to be 0.15 pmol/ml. For each patient, the 
serum levels were measured twice, and the results were 
averaged.
Statistical analysis
Demographic and clinical data of the groups were com-
pared using a Chi squared test and a t-test. Omentin-1 
serum levels were compared with a Mann–Whitney, 
Kruskal–Wallis and Dunn’s Multiple Comparison, when 
appropriate. A log transformation was applied to the not 
normally distributed variables (fasting glucose, glycated 
hemoglobin, triglyceride, and omentin-1 levels) prior 
to performing further analysis. A multivariate stepwise 
logistic regression analysis was performed, adjusted for 
traditional risk factors and omentin-1 levels. The area 
under the receiver operating characteristics (ROC) curve 
was calculated to test the predictive discrimination of 
PAD. All analyses were performed using STATA version 
11.0 for Windows (Statistics/Data Analysis, Stata Corpo-
ration, College Station, TX, USA). Statistical significance 
was established at P < 0.05.
Results
The demographic and clinical characteristics of dia-
betic patients with PAD (indicated as PAD in Table 2) 
and without PAD (WPAD) are summarized in Table 2. 
Among the 600 diabetic patients enrolled in the study, 
300 were included as PAD, and 300 as WPAD. PAD 
patients were more often smokers (P = 0.011), had 
higher blood pressure values (P = 0.010), had more 
frequent coronary artery disease (defined as a his-
tory of ischemic heart disease and/or previous coro-
nary revascularization) (P = 0.022), and had higher 
Table 2 Demographic and  clinical data of  diabetic 
subjects with and without PAD
WPAD (n  =  300) PAD (n  =  300) P value
ABI (years  ±  SD) 1.12  ±  0.5 0.67  ±  0.3 0.009
Men/female (n) 199:101 210:90 0.66
Age (years  ±  SD) 73.2  ±  9.1 76.1  ±  5.1 0.19
BMI (kg/m2) 26.2 ± 3.1 25.6 ± 4.2 0.83
Smoking (current) (%) 84 (28.0) 156 (52.0) 0.011
Hypertension (%) 158 (52.6) 201 (67.0) 0.010
CAD (%) 101 (33.6) 186 (62.0) 0.022
Heart failure (%) 33 (11.0) 38 (12.7) 0.82
Diabetes duration 
(years  ±  SD)
10.1  ±  2.1 11.3  ±  4.1 0.48
Total cholesterol 
(mmol/l)
5.54 (1.12) 5.98 (1.28) 0.78
HDL-C (mmol/l) 1.41 (1.13) 1.31 (1.14) 0.59
LDL-C (mmol/l) 2.13 (1.22) 2.97 (1.23) 0.02
Triglyceride (mmol/l) 2.12 (1.42) 2.33 (1.47) 0.78
Fasting glucose (mmol/l) 7.22 (1.13) 7.22 (1.43) 0.76
Glycated hemoglobin 
(%)
7.18 (1.87) 7.94 (1.87) 0.76
eGFR (ml/min per 1.73 
 m2)
69.23 (11.03) 65.92 (9.12) 0.32
Treatment
  Diet only (%) 44 (14.6) 31 (10.3) 0.36
  Oral agents (%) 164 (54.6) 175 (58.3) 0.87
  Insulin therapy (%) 92 (30.6) 125 (41.6) 0.12
PAD
  1-Fontaine’s II (%) 168 (56.0)
  2-Fontaine’s III (%) 72 (24.0
  2-Fontaine’s IV (%) 60 (20.0)
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LDL-cholesterol values (P = 0.02) than WPAD patients. 
There were no significant differences between groups 
regarding sex (P = 0.66), age (P = 0.19), body mass index 
(BMI) (P = 0.83), heart failure (P = 0.82), mean dura-
tion of diabetes (P = 0.48), fasting glucose (P = 0.76), 
glycated hemoglobin (P = 0.76), eGFR (P = 0.32), total 
cholesterol (TC) (P = 0.78), HDL-cholesterol (P = 0.59), 
and triglyceride (P = 0.78). No statistical difference in 
terms of diabetic therapy was observed between the 
two patient groups. According to the Fontaine’s classifi-
cation, 168 patients were defined as stage II, 72 as stage 
III, and 60 as stage IV.
Omentin-1 levels were lower among patients with 
PAD (29.46 ± 2.32  ng/ml) than among those with-
out PAD (49.24 ± 6.44 ng/ml), as highlighted in Fig. 1. 
Moreover, when evaluating omentin-1 concentration 
according to patients’ functional status, we observed a 
distinct trend, with lower levels of circulating omen-
tin-1 in patients with more severe disease (Fig. 2).
The multivariate logistic regression analysis showed 
that, after adjustments for the cardiovascular risk fac-
tors age, male sex, BMI, eGFR, smoking, hypertension, 
ABI, CAD, heart failure, LDL-cholesterol, and omen-
tin-1 levels, only ABI (OR 7.12, P = 0.011) and LDL-
cholesterol (OR 2.37, P = 0.025) were independent 
determinants for the presence of PAD in patients with 
T2DM. Interestingly, there was an inverse relationship 
between omentin-1 levels and PAD in our diabetic pop-
ulation (OR 0.90, P < 0.001) (Table 3).
The ability of the area under the ROC curve based 
on omentin-1 levels to predict the presence of PAD in 
diabetic patients was 0.968 (Fig. 3) and the best cut-off 
value of omentin-1 for prediction of the occurrence of 
PAD in our population was < 37.57  ng/ml (Sensitivity 
97%, Specificity 96.33%).
Discussion
Peripheral arterial disease is an endemic problem, with 
high direct and indirect social costs. Patients with PAD 
are often unable to work, require frequent hospitaliza-
tions, and often undergo major amputations [20, 24–26]. 
Considering the relevance of the disease, the ability to 
make an early diagnosis of PAD in diabetic patients is 
becoming increasingly important. Of the various diag-
nostic tests available, none of them is currently sensitive 
and specific enough to make an early diagnosis, and often 
the patient consults the specialist when the disease is 
already well advanced.
Inflammation plays a fundamental role in the forma-
tion of atherosclerotic plaque, particularly in the diabetic 
patient. A state of latent chronic inflammation can result 
from the initiation and progression of atherosclerotic 
disease. This inflammation is linked to different path-
ways, is mediated by hyperglycemia, and altered by the 
oxidation–reduction status and the release of inflamma-
tory cytokines [27–29]. Adipose tissue is a very impor-
tant source of inflammation, through the secretion of 
cytokines that directly or indirectly promote inflamma-
tory pathways [30]. Among the various cytokines pro-
duced by adipose tissue, adipokines represent a pool 
responsible for various detrimental or protective pro-
cesses [6, 30, 31]. For this reason, we wanted to evalu-
ate the role of an easy-to-measure adipokine in diabetic 
patients. We found that omentin-1 is reduced in diabetic 
Fig. 1 Omentin-1 levels according to PAD diagnosis. On the box 
plots, central lines represent the median, the length of the box 
represents the interquartile range and the lines extend to minimum 
and maximum values. Omentin-1 levels were lower among patients 
with PAD than among those without PAD (**P < 0.001)
Fig. 2 Omentin-1 levels according to PAD severity. On the box 
plots, central lines represent the median, the length of the box 
represents the interquartile range and the lines extend to minimum 
and maximum values. According to patients’ functional status, 
represented by the Leriche-Fontaine classification, lower levels of 
circulating omentin-1 in patients with more severe disease were 
detected (LF II vs LF III, *P < 0.05; LF III vs LF IV, *P < 0.05)
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patients with PAD and that omentin-1 serum levels are 
statistically significantly lower in T2DM patients with 
PAD than in diabetic patients without PAD. This result 
is very interesting because the relationship between 
omentin and PAD in T2DM has never been documented 
before. In fact, Onur and colleagues have evaluated, in a 
cross-sectional and observational study, the association 
between the levels of omentin-1 and PAD of the lower 
limbs, demonstrating how the serum levels of this adi-
pokine are lower in patients affected by PAD compared 
to healthy controls [19]. This study confirms that this 
adipokine is not only part of the energy balance but has 
a protective effect in diabetic patients, being involved 
in the lipid metabolism and inflammation that cause 
the vascular complications of diabetes. As already men-
tioned, omentin-1 levels are negatively associated with 
diabetes and metabolic syndrome and are reduced in dia-
betic patients with carotid atherosclerosis [11, 12]. The 
protective effect of omentin-1 could be explained by the 
suppression of inflammation and apoptosis of endothe-
lial cells [6, 32]. To our knowledge, this is the first time 
that reduced omentin-1 serum levels were assessed as 
a potential biomarker for PAD in a diabetic popula-
tion. Furthermore, we also demonstrated that omen-
tin-1 serum levels decrease according to disease severity. 
This is a further important finding because, within the 
diabetic population affected by PAD, the values of omen-
tin-1 could help to stratify patients to facilitate a more 
appropriate diagnostic and therapeutic process. Finally, 
we have documented that the relationship between lower 
omentin-1 levels and PAD in T2DM remains significant 
also after adjustment for potential confounding vari-
ables such as age, smoking status, hypertension, CAD, 
heart failure and serum lipid profile. If such a result is 
confirmed, the determination of omentin-1 serum levels 
could prove to be a new biomarker for early diagnosis 
and an effective follow-up of PAD in diabetic patients.
A limitation of our study is that its cross-sectional 
nature is not able to establish causal relationships 
between the findings. We need prospective data to con-
firm these results and to examine whether lower omen-
tin-1 levels may also suffice as an effective biomarker for 
PAD in patients with type-2 diabetes. A further limita-
tion is that we did not use a healthy control population 
to determine normal levels of omentin-1. In fact, there 
is no unequivocal evidence regarding the normal levels 
of omentin-1 [33–35]. Another limitation of the study is 
that we have not considered the distribution of adipose 
tissue in patients, and it is conceivable that a different 
distribution of fat, other than the one measured by the 
simple body mass index, could influence the levels of 
omentin-1. A further confounding factor is that we have 
not considered therapy among the significant variables, 
and it is possible that statins and hypoglycemic agents 
can play a role in the homeostasis of this adipokine. An 
additional limitation of our study is that we have not 
made a distinction between the type of antidiabetic ther-
apy and the levels of omentin-1. Furthermore, it was not 
possible to study a relationship between aerobic exercise 
and the levels of this adipokine. Indeed, Menzel and cow-
orkers suggest how different metabolic conditions can 
influence omentin levels, and this might also have hap-
pened in our model [17]. Finally, genetic analysis could 
help to better define the relationship between omentin-1 
and PAD in diabetic patients. In fact, Jamshidi and col-
leagues evaluated the correlation between the poly-
morphism of the omentin Val109Asp gene—a missense 
variant of exon 4—and the risk of coronary artery disease 
[36]. Such a study of polymorphisms in our population 
could potentially provide interesting data.
Conclusion
In conclusion, we have shown that a relationship exists 
between omentin-1 levels and the presence of PAD in a 
diabetic population, that omentin-1 levels are reduced in 
T2DM affected by PAD, and that omentin-1 levels corre-
late with disease severity. Although further confirmations 
are necessary, these findings could foster earlier diagnosis 
and better management of this widespread disease.
Table 3 Multivariable stepwise logistic regression model 
for  presence of  PAD adjusted for  common risk factors 
and for omentin-1
Variable OR (95% CI) z P value
ABI 7.12 (2.44–9.51) 3.31 0.011
LDL-cholesterol 3.12 (1.18–4.28) 2.43 0.015
Omentin 0.88 (0.77–0.96) − 5.11 < 0.001
Fig. 3 ROC curve analysis of the ability of omentin-1 to predict the 
presence of PAD in diabetic patients. The ability of the area under the 
ROC curve was 0.968
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